StreetInsider.com News Articles

Erasca, Inc (ERAS) 3500 contracts of December 15 calls trade

Tue, 10 Mar 2026 15:09:03 -0400

Erasca, Inc (NASDAQ: ERAS) 30-day option implied volatility is at 121; compared to its 52-week range of 73 to 179 with a focus on 3500 contracts of December 15 calls.

Erasca Inc (ERAS) PT Raised to $20 at Stifel

Tue, 10 Mar 2026 14:36:19 -0400

Stifel analyst Laura Prendergast raised the price target on Erasca Inc (NASDAQ: ERAS) to $20.00 (from $10.00) while maintaining a Buy rating.

The analyst commented, "We reiterate our Buy rating on Erasca (ERAS) and increase our target price to $20 (previously $10). Our new target price assumes ERAS-0015 (pan-RAS) data in 1H26 will look slightly differentiated to RVMD's early daraxonrasib safety/efficacy. We model ERAS generating ~$3.2B in global revenue by 2035 (~20% of our RVMD 2035 revenue estimate). Today, ERAS announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech to include China, Hong Kong and

Erasca Inc (ERAS) PT Raised to $20 at Stifel

Tue, 10 Mar 2026 14:36:19 -0400

Stifel analyst Laura Prendergast raised the price target on Erasca Inc (NASDAQ: ERAS) to $20.00 (from $10.00) while maintaining a Buy rating.

Erasca expands ERAS-0015 license to secure worldwide rights

Tue, 10 Mar 2026 08:03:23 -0400

Erasca Inc. (NASDAQ: ERAS) exercised an option to expand its licensing agreement with Joyo Pharmatech Co., Ltd. to include China, Hong Kong, and Macau, securing worldwide rights for its pan-RAS molecular glue ERAS-0015, the company announced.

Under the expanded agreement terms, Erasca will make a one-time payment to Joyo based on the development program stage. The company previously held licensing rights for ERAS-0015 in territories excluding China, Hong Kong, and Macau.

ERAS-0015 is an oral pan-RAS molecular glue being evaluated in the AURORAS-1 Phase 1 trial for patients with RAS-mutant solid tumors. The company expects initial Phase 1 monotherapy data in the

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Tue, 10 Mar 2026 08:00:00 -0400

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy

ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent

Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Tue, 10 Mar 2026 08:00:00 -0400

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy

ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent

Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Tue, 10 Mar 2026 08:00:00 -0400

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy

ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent

Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Tue, 10 Mar 2026 08:00:00 -0400

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy

ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent

Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026

Form 4 Erasca, Inc. For: Mar 04 Filed by: Morris Shannon

Fri, 06 Mar 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260306/26122812.html

Form 4 Erasca, Inc. For: Mar 04 Filed by: Morris Shannon

Fri, 06 Mar 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260306/26122812.html

Erasca Inc (ERAS) PT Raised to $20 at Clear Street

Thu, 05 Mar 2026 17:16:16 -0400

Clear Street analyst Kaveri Pohlman raised the price target on Erasca Inc (NASDAQ: ERAS) to $20.00 (from $11.00) while maintaining a Buy rating.

The analyst commented, "Erasca announced a clinical trial and supply agreement (CTCSA) with Tango Therapeutics (TNGX, NC) to evaluate ERAS-0015 in combination with Tango’s PRMT5 inhibitor, vopimetostat (TNG462). We view this as a capital-efficient initiative that increases ERAS-0015’s combination flexibility and brings an MTAPdel RASm approach. We raise our PT to $20 (from $11) based on (1) higher PoS for ERAS-0015—55% in PDAC, 40% in NSCLC (up from 30% each), reflecting notable MTAP deficiency prevalence (35% for PDAC,

Erasca Inc (ERAS) PT Raised to $20 at Clear Street

Thu, 05 Mar 2026 17:16:16 -0400

Clear Street analyst Kaveri Pohlman raised the price target on Erasca Inc (NASDAQ: ERAS) to $20.00 (from $11.00) while maintaining a Buy rating.

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Thu, 05 Mar 2026 07:01:00 -0400

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat

Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (Nasdaq: TNGX; “Tango”) to evaluate Erasca’s pan-RAS molecular glue, ERAS-0015, with Tango’s PRMT5 inhibitor, vopimetostat (TNG462).

“We’ve disclosed encouraging early

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Thu, 05 Mar 2026 07:01:00 -0400

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat

Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost

“We’ve disclosed encouraging early

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Thu, 05 Mar 2026 07:01:00 -0400

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat

Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost

“We’ve disclosed encouraging early

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Thu, 05 Mar 2026 07:01:00 -0400

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat

Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost

“We’ve disclosed encouraging early

Form 144 Erasca, Inc. Filed by: Morris Shannon

Wed, 04 Mar 2026 17:39:00 -0400

si-local-file:///var/storage/secattach/20260304/26112957.html

Form 144 Erasca, Inc. Filed by: Morris Shannon

Wed, 04 Mar 2026 17:39:00 -0400

si-local-file:///var/storage/secattach/20260304/26112957.html

Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Tue, 24 Feb 2026 08:00:00 -0400

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043

Expands Erasca’s diversified IP portfolio for RAS-driven cancers